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Abstract
Introduction: Prevalence of an abnormal Papanicolaou smear was significantly increased in lupus patients in cross-
sectional studies, associated with a higher prevalence of high-risk human papillomavirus (HPV) infection. The
nucleic acid-specific Toll-like receptors (TLRs) locate at the endolysosomal compartments and trigger the induction
of cytokines for the innate immune response. This study evaluated whether abnormal host innate immune
response in lupus patients may enhance HPV persistence.
Methods: Protein levels of TLRs 3, 7, 8 and 9 in cervical epithelial cells of lupus patients and controls with or
without HPV infection were assessed using flow cytometry. Characteristics associated with the differential
expression of TLRs in systemic lupus erythematosus (SLE) were elucidated. The effect and interferon-stimulated
genes (ISGs) (ISG15 and Mx-1) gene expressions were then measured in oncogenic HeLa (HPV18), CaSki (HPV) and
C33A (HPV negative) cell lines using flow cytometry and quantitative real-time PCR. Ex vivo productions of
cytokines and interferon-gamma (IFN-g) upon TLR ligands stimulations were subsequently measured using
cytometric bead array and ELISA.
Results: For subjects with HPV infection, levels of TLR3 and TLR7 were significantly lower in lupus patients
compared with controls. Significantly decreased TLRs 7, 8 and 9 levels were observed in HPV-negative SLE
compared to healthy controls. For SLE with and without HPV infection, TLR7 and 9 levels were significantly lower
in infected SLE than those in HPV-negative patients. Independent explanatory variables associated with down-
regulation of TLR7 level included HPV infection and a higher cumulative dose of prednisolone; while a higher
cumulative dose of hydroxychloroquine and HPV infection were associated with down-regulation of TLR9 level. In
cervical cell lines, TLRs 3, 7, 8, 9 protein levels and antiviral ISG15 and Mx-1 gene expressions were inhibited in two
oncogenic HPV types. Functional data showed that the induction of pro-inflammatory cytokines by TLR ligands
(R837, ssRNA and ODN2395) was greatly impaired in CaSki and HeLa than C33A cells.
Conclusions: In conclusion, prednisolone and TLR antagonist (hydroxychloroquine) may down-regulate protein
levels of TLR7 and TLR9 in lupus patients, thereby decreasing the innate immune response against HPV infection.
Upon infection, HPV further down-regulate TLR7 and 9 levels for viral persistence. Furthermore, reduction of nucleic
acid-sensing TLRs 7, 8 and 9 in carcinogenic HPVs ensures that the expression of inducible pro-inflammatory
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cytokines is minimized to prevent the expression of antiviral ISGs (ISG15 and Mx-1) on a biologically relevant
antiviral response.
Introduction
Persistent infection with an oncogenic human papillo-
mavirus (HPV)16 or 18 is thought to be necessary for
the development of invasive cervical cancer, particularly
among immunocompromised patients [1]. Previous stu-
dies have revealed an increase in the prevalence of
abnormal Papanicolaou (Pap) smears among patients
with systemic lupus erythematosus (SLE) [2,3]. Indepen-
dent risk factors associated with the development of
squamous intraepithelial lesion (SIL) in lupus patients
included persistent oncogenic HPV infection and the
use of cyclophosphamide [4]. Although the majority of
the otherwise healthy individuals clear HPV infection
with time, almost half (48.5%) of the newly acquired
HPV infections persisted for at least six months in lupus
patients [5]. However, none of the clinical, lifestyle,
gynecological and treatment regime characteristics was
predictive of persistent HPV infection in lupus patients
[4].
Innate immune recognition of viral infection triggers
antiviral immune responses [6,7]. Viral nucleic acids act
as pathogen-associated molecular patterns and are
recognized by multiple TLRs. Intracellular TLRs 3, 7, 8
and 9 are involved in the recognition of viral nucleo-
tides, such as double-stranded RNA (dsRNA) (TLR3),
single-stranded RNA (ssRNA) (TLR7-TLR8) and DNA
(TLR9) [8]. Papillomavirus is a small dsDNA virus. It
has been suggested that DNA viruses might produce
RNA transcripts that engage TLR3 [9]. Pattern recogni-
tion receptor (PRR) signalling can be suppressed by the
inhibition of downstream signalling or sequestration of
typical viral nucleic acids, thereby inhibiting viral recog-
nition [10]. In SLE patients, factors regulating the levels
of TLRs include inflammation, as reflected by systemic
lupus erythematosus disease activity index (SLEDAI),
which may up-regulate TLR levels in peripheral blood
mononuclear cells (PBMCs) [11,12]. In addition, TLR9
can induce anti-dsDNA antibody production, and pro-
inflammatory cytokines may also up-regulate TLR levels
[13]. On the other hand, factors which may down-regu-
late TLRs include the use of high-dose prednisolone and
TLR antagonists, such as hydroxychloroquine [14,15].
However, whether the abnormal host innate immune
response in lupus patients may play a role in enhancing
HPV persistence remained unknown.
Type I interferons (IFNs) are key effector molecules of
the innate immune system and are essential for the anti-
viral response towards a plethora of viruses [16]. Nucleic
acid-sensing TLRs play a critical role in antiviral
immunity by inducing the downstream of IFNs, includ-
ing IFN-a, IFN-b and IFN-g, and other TLR-induced
inflammatory cytokines [6]. Recent genome-wide tran-
scriptome analysis indicates that the expression of inter-
feron-stimulated genes (ISGs) and pathogen receptors
are inhibited by oncogenic HPV types [17-19], but the
details of the mechanisms remained uncertain. As many
viruses have adopted mechanisms to escape from TLR
recognition by blocking IFN-mediated responses
induced via TLR-dependent and -independent cascades
[17,20,21], carcinogenic HPVs may inhibit both antiviral
ISGs and nucleic acid-sensing TLRs for a biologically
relevant antiviral response in HPV16, 18 and 31
[17-19,22,23]. Whether these nucleic acid-sensing TLRs,
IFN-g and ISGs (ISG15 and Mx1 (myxovirus resis-
tance)), which have been shown to function as antiviral
effectors during HPV infection [17,24] and markers for
patients with severe lupus [25], may be different in cell
lines harboring HPV16 (CaSki) and 18 (HeLa) genomes
compared to HPV-negative (C33A) cells has never been
explored.
The aims of this cross-sectional study included the
following: 1) To compare the protein levels of TLRs 3,
7, 8 and 9 in cervical epithelial cells of SLE patients and
controls with or without HPV infection; 2) To ascertain
the potential explanatory clinical and laboratory vari-
ables associated with TLR protein levels in cervical
epithelial cells; 3) To investigate whether the reduced
TLR protein levels has functional consequences for cyto-
kine induction. Our findings showed that prednisolone
and hydroxychloroquine may down-regulate levels of
TLR7 and TLR9, respectively. Interestingly, upon infec-
tion, HPV further down-regulates TLR7 and TLR9 levels
in lupus patients, which is consistent with previous
reports showing that oncogenic HPV16 may suppress
the host immune response by down-regulating the
TLR9 transcript and, subsequently, limit its ability to
induce the transcription of pro-inflammatory genes for
antiviral immune responses [23].
Materials and methods
Subjects
One hundred and fifty consecutive female patients
attending the lupus clinic at The Prince of Wales Hospi-
tal of The Chinese University of Hong Kong, who ful-
filled the 1997 American College of Rheumatology
revised criteria for the classification of SLE [26], and
participated in a prospective study on SLE and cervical
intraepithelial neoplasia, were recruited for this cross-
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sectional study. Details of the previous study have been
described elsewhere [4]. Briefly, subjects were eligible
for the study if they were married or sexually active.
Excluded were subjects who were pregnant or under
treatment for invasive cervical cancer. None of the sub-
jects had received HPV vaccine. Twenty-nine age-
matched female Chinese volunteers were recruited as
controls.
Subjects were divided into four groups based on the
following criteria: Group 1 - SLE patients with positive
HPV DNA (n = 15); Group 2 - SLE with negative HPV
DNA (n = 31); Group 3 - control subjects with positive
HPV DNA (control subjects referred for colposcopy
because of abnormal cytology) (n = 7); and Group 4 -
healthy controls with negative HPV DNA (healthy
women for screening at the Well Women Clinic, Hong
Kong) (n = 22)
All women with abnormal cytology (atypical squamous
cells of undetermined significance (ASCUS) or worse) or
positive HPV DNA were referred for colposcopy and
cervical biopsy to obtain histological diagnosis. Ethics
approval has been obtained from the Ethics Committee
of The Chinese University of Hong Kong, and informed
consent was obtained from all participants according to
the Declaration of Helsinki.
Clinical and laboratory parameters
The study visit included a structured interview with a
standardized questionnaire. Clinical assessment and
blood collection for the determination of disease activity,
gynecologic examination for the collection of specimens
for a Pap test, and HPV testing were performed. Medi-
cation history for the past 15 years was retrieved from
case notes. Physical examinations and laboratory investi-
gations, including complete blood count, liver and renal
functions, anti-dsDNA titer, serum complements C3
and C4 levels, were performed at study visit. The SLE-
DAI and Systemic Lupus International Collaborating
Clinics/American College of Rheumatology damage
index (SLICC) were evaluated during the clinical assess-
ment [27,28]. Major organ involvement was present if
the disease affected any of the following systems: neu-
ropsychiatric, kidney, heart and hematologic (hemolytic
anemia, platelet < 100,000/μl). Immunosuppressive
agents included prednisolone, hydroxychlorlquine,
azathioprine, cyclophosphamide (oral or IV), cyclosporin
A (CsA) and mycophenolate mofetil (MMF).
HPV sampling procedure and identification
The method of cervical sample collection, detection and
identification of HPVs has been described previously
[29]. Briefly, two cervical samples were collected with a
Cervex brush (Rovers Medical Devices, Netherlands)
from each woman. The first sample for routine liquid
based cytologic examination and the second sample for
FACS analysis were immersed in 10 mL of phosphate
buffered saline (PBS, Gibco Laboratories, Grand Island,
NY, USA) and Dulbecco’s modified Eagle’s minimal
essential medium/F12 medium (DMEM) (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% defined
fetal bovine serum (FBS) (Invitrogen), respectively. Sam-
ples were then agitated vigorously for dislodging the
residual cervical cells. After cytologic examination, the
remained sample was used for HPV DNA detection.
DNA was extracted and then detected by the PGMY
polymerase chain reaction (PCR) targeting the consen-
sus region of the HPV L1 gene [29-31]. Samples tested
positive for HPV DNA were subjected to Linear Array
HPV Genotyping Test that can detect 37 types of HPV.
HPV types were grouped as high-risk and low-risk [29].
The second cervical sample collected in 10% FCS-
DMEM was immediately transported for flow cytometric
analysis.
Flow cytometric gating for cervical epithelial population
Cervical cell pellets (1 × 106 cells) were resuspended and
blocked with 2% human pooled serum for blocking the
non-specific Fc receptors. Leukocytes were phenotyped by
staining with anti-CD45 antibody using R-phycoerythin
(PE) mouse IgG1 isotypic control (Biolegend Inc, San
Diego, CA, USA) as background control. The cells were
then fixed and permeabilized using Fix/Perm solution (BD
Biosciences Corp., San Diego, CA, USA). Purified mouse
anti-cytokeratin antibody (Millipore Inc., Billerica, MA,
USA) and mouse IgG1 isptypic control (BD Biosciences)
were used for intracellular staining, together with a fluor-
escein iso-thiocyanate (FITC) secondary antibody (Zymed
Laboratories Inc., South San Francisco, CA, USA). The
side scatter (SSC), forward scatter (FSC) and florescence
signal of 10,000 epithelial cells were then acquired and
analysed by flow cytometer using CellQuest™ software
(FACSCalibur, BD Biosciences).
Flow cytometric analysis of intracellular TLRs
Serum-blocked cervical epithelial cells, HeLa, CaSki and
C33A cells were fixed and permeabilized as previously
mentioned. FITC-conjugated antibodies for TLRs 3, 8, 9,
PE-conjugated TLR7 antibody (Imgenex, San Diego, CA,
USA) and corresponding FITC-conjugated IgG isotypic
control (BD Biosciences) and PE-conjugated mouse
IgG1,  (Biolegend) were incubated with cells for 30
minutes at 4°C. The levels of TLRs in 10,000 epithelial
cells were assessed using flow cytometer and the results
were expressed as mean fluorescence intensity (MFI).
Cell culture
HeLa (ATCC, CCL-2) and C33A cells (ATCC, HTB-31)
were purchased from American Type Culture Collection
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(ATCC, Manassas, VA, USA) and maintained in MEM-
Earle medium (Sigma-Aldrich Corp., St. Louis, MO,
USA), supplemented with 10% FBS, 60 mg/l gentamy-
cine and 1% non-essential amino acid (Biochrom, Berlin,
Germany). Sodium pyruvate (5%) (Sigma) was added for
C33A cells. CaSki cells (ATCC, CRL-1550) obtained
from ATCC was grown in RPMI1640 medium (Sigma)
containing 10% FBS, 60 mg/ml gentamycine and 1%
non-essential amino acid. Cells (5 × 105 cells) were
incubated with or without TLR ligand Poly (I:C) (TLR3
ligand, Sigma) and ODN2395 (TLR9 ligand, InvivoGen,
San Diego, CA, USA) at 10 μg/ml each and R837/Imi-
quimod (TLR7 ligand) and ssRNA (TLR8 ligand) at 5
μg/ml each for 24 h at 37°C in a 5% CO2 atmosphere.
The cell-free supernatant was harvested and stored at
-70°C for subsequent assays of IFN-g and cytokines.
Quantitative real-time PCR of ISGs (ISG15 and Mx1) gene
expressions
Total RNAs of Caski, HeLa or C33A were extracted
using RNeasy Mini Kit (Qiagen Inc., Valencia, CA,
USA). All RNA samples were treated with DNase I
(Invitrogen) and reversely transcribed to cDNA with
TaqMan Reverse Transcription Reagents (Applied Bio-
systems Inc., Foster city, CA, USA). The mRNA ISG15,
Mx1 and GAPDH (endogenous control) was quantified
by real-time PCR using SYBR Green probe (Roche
Diagnostics Corp., Indianapolis, IN, USA) with the use
of Applied Biosystems’ 48-well StepOne™ Real Time
PCR System. The primers of human ISG15, Mx1 and




T-3’) and reverse (5’-GGCGATGGCATTCTGGGCTT
TAT-3’); GAPDH forward (5’-ATGGGGAAGGTGAA
GGTCG-3’) and reverse (5’-GGGGTCATTGATGG-
CAACAATA-3’). Real-time PCR was performed in a
25ul reaction mixture containing primers, FastStart Uni-
versal SYBR Green master (ROX) reagent (Roche) and
cDNA sample in duplicate. The real-time PCR reaction
was performed as previously described [33].
Quantitative analysis of IL-1b, IL-6, IL-8, IL-10, IL-12, TNF-
a and IFN-g
The concentration of cytokines, including interleukin
(IL-6), IL-8, IL-10 and IL-12p70, tumor necrosis (TNF)-
a and IL-1b in culture supernatant with equal cell num-
ber loading, were measured simultaneously using human
inflammatory cytokine Cytometric Bead Array (CBA,
BD Pharmingen, San Diego, CA, USA) with flow cyto-
metry (FACSCalibur, BD Biosciences) [34]. Human IFN-
g in culture supernatant was assayed by enzyme-linked
immunosorbent assay (ELISA) reagent kit (R&D
systems, Minneapolis, MN, USA). The range of detec-
tion was 15.6 to 1,000 pg/ml for ELISAs and 20 to 5,000
pg/ml for CBA.
Statistical analysis
Results were expressed as mean ± S.D. for normally dis-
tributed data. Non-normally distributed data were
expressed as median (interquartile range, IQR). Chi-
squared tests were used for categorical variables. For
continuous variables, the Student’s t test or Mann-Whit-
ney U test was used where appropriate. Association
between the potential explanatory variables and TLRs
level were tested using Chi-squared tests for categorical
variables and Pearson’s or Spearman’s correlation for
continuous variables with normal and skewed distribu-
tion, respectively. Variables with P < 0.05 in the univari-
ate analysis were entered into linear regression analysis
(enter). Variables that were skewed were logarithmically
transformed before entering the regression analysis. All
hypotheses were two-tailed, and P-value < 0.05 were
considered significant. The Statistics Package for Social
Sciences (SPSS for Windows, version 13.0, 2006, SPSS
Inc., Chicago, IL, USA) was used for the analysis.
Results
Pap smear findings, socio-demographic, behavioral and
clinical characteristics
The prevalence of cytological abnormality was signifi-
cantly higher in HPV-positive subjects (Group 1 vs
Group 2: 53% vs 3% and Group 3 vs Group 4: 71% vs
14%) (Table 1). Socio-demographic and gynaecologic
characteristics of controls with and without HPV infec-
tions (Groups 3 and 4) were similar, except the unem-
ployment rate and the prevalence of having multiple
sexual partners were increased in Group 3. In those sub-
jects without HPV infection, a higher prevalence of
menopause and unemployment was observed in the SLE
patients (Group 2) compared with healthy controls
(Group 4). SLE patients with HPV infection (Group 1)
had a significantly longer disease duration, a higher pre-
valence of at least two major organ involvement, hema-
tologic involvement, and the use of hydroxychloroquine
when compare to Group 2 (all P <0.05) (Table 2). The
prevalence of multiple (≥ 2) HPV infections, infection
by high-risk or low-risk HPV type, or HPV subtypes
was similar in SLE patients (Group 1) and controls
(Group 3) (data not shown).
Protein level of TLRs 3, 7, 8 and 9 in the cervical
epithelial cells of lupus patients and controls
The protein levels of TLRs 3, 7, 8 and 9 in gated cyto-
keratin+CD45- cervical epithelial cells (Figure 1a) of
lupus patients and controls were shown in the scatter
plots as MFI (Figure 1b). For subjects with HPV
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infection (Groups 1 and 3), TLR3 and TLR7 levels were
significantly lower in lupus patients compared with con-
trols. Significantly decreased levels of TLRs 7, 8 and 9
were observed in HPV-negative SLE compared to
healthy controls (Groups 2 and 4). TLR7 and TLR9
levels were significantly lower in HPV-DNA positive
than HPV-DNA negative SLE patients (Groups 1 and 2).
No significant differences in the levels of TLRs 3, 7, 8
and 9 was found between controls with and without
HPV infection (Groups 3 and 4) (all P > 0.05).
Potential explanatory variables associated with TLR levels
in lupus patients
Tables 3 and 4 summarized the association between
clinical, treatment regime characteristics and levels of
TLRs 3, 7, 8 and 9 assessed by univariate analysis (Table
3: continuous variables, Table 4: categorical variables).
There was a significantly positive correlation between
the SLEDAI and TLR9 level (Table 3). Significantly posi-
tive correlation was found between TLR8 level and titers
of anti-dsDNA (P < 0.05) (Table 3). Regarding the role
of immunosuppressants, a higher cumulative dose of
prednisolone was inversely correlated with TLR7 level
(Table 3). Moreover, TLR9 level was negatively corre-
lated with the cumulative dose of hydroxychloroquine
and the duration of azathioprine treatment during the
past 15 years. In contrast, TLR3 level was positively cor-
related with the cumulative dose of CsA (Table 3). The
TLR7 level was significantly lower in patients treated
with hydroxychloroquine compared to those having
never been treated with hydroxychloroquine. Signifi-
cantly decreased level of TLR7 was found in patients
infected with high-risk HPV types compared with those
without high-risk HPVinfection (all P < 0.05) (Table 4).
Using regression analysis, HPV infection and a higher
cumulative dose of prednisolone in the past 15 years
were independent explanatory variables associated with
down-regulation of TLR7 level in SLE (both P < 0.05)
(Table 5). Moreover, HPV infection, a lower SLEDAI
and a higher cumulative dose of hydroxychloroquine in
the past 15 years were independent risk factors for
down-regulating TLR9 level in SLE (all P < 0.05) (Table
5).
TLRs and ISGs expressions are inhibited by oncogenic
HPVs
The protein levels of TLRs 3, 7, 8 and 9 were reduced in
CaSki and HeLa when compared with C33A cells,
respectively (Figure 2a). In addition, all expressions of
intracellular TLRs were consistently reduced in CaSki
Table 1 Pap smear findings, socio-demographic and behavioral characteristics of lupus patients and control subjects #














Cytological abnormality * 8 (53) 1 (3) ††† 5 (71) 3 (14) ‡‡
Demographic & social characteristics
Age at study, mean ± S.D. (range), year 45 ± 10 (28 to 58) 47 ± 10 (30 to 63) 41 ± 10 (31 to 59) 44 ± 11 (25 to 62)
Menopause 7 (47) 17 (55) 2 (29) 4 (18) §§
Married 9 (60) 24 (77) 7 (100) 17 (77)
Low education level (high school or lower) 12 (80) 25 (81) 7 (100) 15 (68)
Monthly family income ≤ HK$ 10,000 6 (40) 9 (29) 1 (14) 6 (27)
Alcohol 0 (0) 3 (10) 1 (14) 1 (5)
Current smoker 0 (0) 3 (10) 1 (14) 1 (5)
Employment 7 (47) 11 (35) 2 (29) 18 (82) ‡‡, §§
Reproductive and gynecologic characteristics
First intercourse at young age (≤ 17 years) 2 (13) 4 (13) 1 (14) 2 (9)
Multiple sexual partners (≥ 3) 3 (20) 2 (6) 4 (57) 1 (5) ‡‡
History of sexually transmitted disease 1 (7) 0 (0) 0 (0) 0 (0)
Oral contraceptives 2 (13) 3 (10) 1 (14) 2 (9)
Condom use by male partner 6 (40) 11 (35) 3 (43) 11 (50)
Current vaginal discharge 0 (0) 2 (6) 0 (0) 1 (5)
Bleeding after intercourse 0 (0) 2 (6) 0 (0) 2 (9)
# Values are the number (percentage) unless otherwise indicated. * Refers to atypical squamous cells of undetermined significance or squamous intraepithelial
lesions. HPV = human papillomavirus; SLE = systemic lupus erythematosus; Group 1 = SLE with positive HPV DNA; Group 2 = SLE with negative HPV DNA; Group
3 = Control subjects with positive HPV DNA; Group 4 = Healthy controls with negative HPV DNA; ††† P <0.001, comparing between SLE patients with and without
HPV infection. ‡‡ P <0.01, comparing between control subjects with and without HPV infection. §§ P < 0.01, comparing between SLE and control subjects without
HPV infection
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compared to HeLa cells with the exception of TLR3
(Figure 2a). Similarly, ISG15 and Mx-1 gene expressions
were down-regulated in CaSki and HeLa when com-
pared to C33A cells, respectively (Figure 2b). Mx-1
expression was reduced in CaSki cells than HeLa cells.
No significant differences of ISG15 gene level between
oncogenic HPV types were observed (Figure 2b).
Induction of inflammatory cytokines by TLR agonists was
impaired in oncogenic HPVs
To investigate whether the reduced TLR protein levels
has functional consequences for cytokine induction,
HeLa, CaSki and C33A cell lines were incubated with
TLRs 3, 7, 8 and 9 ligands, respectively. As shown in
Figure 2c, the addition of TLR9 ligand ODN2395 led to
a clear increase in IL-8, IL-10, IL-12p70, TNF-a and IL-
1b in C33A cells, while a moderate increase was
observed in the presence of the ligands for TLR7 (R837)
and TLR8 (ssRNA). Conversely, the induction of all
cytokines by TLR8 and TLR9 ligands were greatly
impaired in oncogenic HPV types. Similarly, production
of pro-inflammatory cytokines (IL-6, IL-8, IL-12p70,
TNF-a and IL-1b) was strongly inhibited by TLR7
ligand in two cancer-derived HPV cell lines. Strikingly,
no IL-6 and IL-8 inductions were observed in CaSki
cells when stimulated with the ligand for TLR9, indicat-
ing that the oncogenic viral proteins are able to strongly
inhibit the TLR9 pathways. In contrast to the inhibited
TLRs 7, 8 and 9 pathways in oncogenic HPV types,
TLR3 pathway was up-regulated in HeLa cells in com-
parison to CaSki and C33A cells and no obvious differ-
ence between the two different types was apparent
(Figure 2c). The level of IFN-g in three different cell
lines was either undetectable or weak (data not shown).
Discussion
Failure to induce an effective cellular immune response
due to inefficient activation of innate immunity and
ineffective priming of the adaptive immune response in
lupus patients may lead to an increase in susceptibility
and persistence of viral infection, including HPV. Emer-
ging evidence has reported that nucleic acid-sensing
Table 2 Clinical characteristics of patients with systemic lupus erythematosus #
Group 1
(HPV-positive)
(SLE patients = 15)
Group 2
(HPV-negative)
(SLE patients = 31)
Clinical features
SLE duration, mean ± S.D.(range), year 18 ± 8 (6 to 36) 13 ± 6 (5 to 28) †
SLICC, median (IQR) 1 (0 to 2) 0 (0 to 1)
SLEDAI score, median (IQR) 2 (0 to 6) 2 (0 to 4)
Serological features
Serum complement C3, median (IQR), g/l 0.9 (0.7 to 1.1) 0.8 (0.6 to 1.0)
Serum complement C4, median (IQR), g/l 0.2 (0.1 to 0.3) 0.2 (0.1 to 0.3)
Elevated anti-dsDNA (> 100 IU/ml) 6 (40) 13 (42)
Anti-dsDNA titer, median (IQR), IU/ml 308 (210 to 591) 331 (93 to 572)
Major organ involvement ever
0 0 (0) 3 (10)
1 1 (7) 9 (29)
≥ 2 14 (93) 19 (61) †
Neuropsychiatric 3 (20) 10 (32)
Nephritis 12 (80) 17 (55)
Serositis 6 (40) 7 (23)
Hematologic 15 (100) 24 (77) †
Immunosuppressive therapy ever 15 (100) 29 (94)
Prednisolone 14 (93) 24 (77)
Hydroxychloroquine 12 (80) 15 (48) †
Azathioprine 9 (60) 16 (52)
Cyclophosphamide (oral or IV) 2 (13) 5 (16)
Cyclosporin A 2 (13) 7 (23)
Mycophenolate mofetil 3 (20) 5 (16)
# Values are the number (percentage) unless otherwise indicated. * Refers to atypical squamous cells of undetermined significance or squamous intraepithelial
lesions. Anti-dsDNA, anti-double stranded DNA;
IQR, interquartile range; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index; SLICC, systemic lupus international
collaborating clinics/Americal College of Rheumatology damage index. Group 1, SLE with positive HPV DNA; Group 2, SLE with negative HPV DNA; † P <0.05
comparing between SLE patients with and without HPV infection.
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Figure 1 Protein levels of TLRs 3, 7, 8 and 9 in human cervical epithelial cells. (a) Representative do plot analysis showing the respective
gating for cervical epithelial cells (cytokeratin+ CD45-), leucocytes (cytokeratin-CD45+) and cell debris (cytokeratin-CD45-) based on their forward/
sideward scatter characteristics (FSC/SSC) in three independent human cervical samples using flow cytometry. (b) The differential levels of TLRs
3, 7, 8 and 9 in gated cervical epithelial cells were shown in scatter plots as mean fluorescence intensity (MFI). Group 1 = SLE with positive HPV
DNA; Group 2 = SLE with negative HPV DNA; Group 3 = Control subjects with positive HPV DNA; Group 4 = Healthy controls with negative HPV
DNA.
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TLRs seem to play a critical role in recognition of viral
nucleic acids, both with regards to selectivity of their
ligands, pathogens and differential recognition of foreign
versus self nucleic acids [6,7]. An elevated level of these
TLRs has been demonstrated in the PBMCs of lupus
patients compared to healthy controls [11,12]. In con-
trast, this study showed that TLRs 7, 8 and 9 levels were
significantly decreased in the cervical epithelial cells of
HPV-negative lupus patients compare to healthy con-
trols probably because of immunosuppressive therapy.
TLR antagonists, such as hydroxychloroquine, chloro-
quine and quinacrine, appear to be promising for a
number of inflammatory and autoimmune diseases,
especially in lupus patients [15,35]. Derivatives and
small molecule analogues of chloroquine and quinacrine
suppress the over-activation of immune responses
[15,35]. These immunomodulatory drugs are antagonists
of TLR9 and to a lesser extent, TLR7 and TLR8 [14,15].
Hydroxychloroquine, in particular, has been shown to
interfere with the acidification of lysosomal compart-
ments and subsequently inhibit intracellular signaling
through TLR7 and TLR9 [36]. Glucocorticoids are
widely used anti-inflammatory and immunosuppressive
agents. Prednisolone could suppress the functions of
TLR-stimulated human plasmacytoid dendritic cell [37].
Moreover, the administration of TLR7 agonist R848
induces a rapid local and systemic inflammatory
response in mice that could be attenuated by glucocorti-
coids or TNF-a treatment [38]. Oral doses of predniso-
lone resulted in a marked reduction of TLRs 3, 4 and 7
activation by 70 to 90% compared with healthy controls,
demonstrating the potent in vivo pharmacologic effect
of this drug on TLR activity [39]. Although prednisolone
and hydroxychloroquine has been widely used in SLE, in
vivo effects of these agents on TLRs level in SLE have
not been well elucidated. This study was the first to
Table 3 Effects of clinical variables on the TLR levels in lupus patients (continuous variable)
TLR3 TLR7 TLR8 TLR9
n r P n r P n r P n r P
Clinical characteristic
SLE duration, year 46 -0.263 0.279 26 -0.187 0.214 46 0.183 0.222 46 0.064 0.672
SLEDAI score 46 -0.004 0.977 26 -0.030 0.885 46 0.161 0.284 46 0.446 0.002 ††
Anti-dsDNA titer (> 100 IU/ml) 19 0.272 0.261 13 -0.291 0.334 19 0.498 0.030 † 19 -0.094 0.702
Immunosuppressive therapy
Prednisolone
Current dose, mg 36 -0.082 0.636 22 -0.164 0.466 36 0.116 0.502 36 -0.032 0.855
Cumulative dose, gm 38 -0.020 0.898 22 -0.436 0.042 † 38 0.102 0.542 38 0.018 0.916
Duration, months 38 -0.150 0.368 22 -0.223 0.318 38 -0.100 0.555 38 0.017 0.920
Hydroxychloroquine
Current dose, mg 16 0.261 0.329 10 -0.044 0.905 16 -0.226 0.400 16 0.052 0.848
Cumulative dose, gm 27 -0.073 0.716 15 -0.132 0.639 27 -0.193 0.335 27 -0.399 0.039 †
Duration, months 27 -0.106 0.598 15 -0.179 0.524 27 -0.139 0.488 22 -0.081 0.689
Azathioprine
Current dose, mg 8 -0.385 0.346 5 -0.671 0.215 8 0.462 0.249 8 -0.089 0.833
Cumulative dose, gm 25 -0.166 0.429 16 -0.012 0.966 25 -0.336 0.101 25 -0.339 0.098
Duration, months 25 -0.036 0.865 16 -0.118 0.664 25 -0.396 0.505 25 -0.440 0.028 †
Cyclophosphamide (oral or IV)
Current dose, mg 4 -0.316 0.684 2 N.A. N.A. 4 -0.316 0.684 4 -0.316 0.684
Cumulative dose, gm 7 0.107 0.840 3 N.A. N.A. 7 -0.107 0.840 7 -0.500 0.267
Duration, months 7 0.571 0.200 3 N.A. N.A. 7 0.143 0.783 7 -0.393 0.396
Cyclosporin A
Current dose, mg - - - - - - - - - - - -
Cumulative dose, gm 9 0.783 0.013 † 5 0.800 0.133 9 -0.333 0.948 9 -0.283 0.463
Duration, months 9 0.200 0.613 5 0.900 0.083 9 0.167 0.678 9 0.333 0.385
Mycophenolate mofetil, gm
Current dose, mg 5 0.359 0.553 3 N.A. N.A. 5 0.718 0.872 5 0.564 0.322
Cumulative dose, gm 8 0.071 0.935 5 -0.600 0.350 8 -0.429 0.299 8 -0.381 0.360
Duration, months 8 -0.048 0.935 5 -0.700 0.233 8 -0.548 0.171 8 -0.429 0.299
Anti-dsDNA, Anti-double stranded DNA; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index; TLR, toll-like receptor; †
P <0.05, †† P <0.01.
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demonstrate a negative correlation between the cumula-
tive dose of prednisolone and TLR7 level. Similarly,
TLR9 level was found to be negatively correlated with
the cumulative dose of hydroxychloroquine. These find-
ings suggest that prednisolone and TLR antagonists may
down-regulate the level of TLR7 and TLR9 in SLE,
thereby decreasing the ability to clear HPV infection.
Further prospective studies are warranted to confirm or
refute this hypothesis.
Another novel finding from this study was the down-
regulation of TLR3 and TLR7 levels in HPV-infected
SLE compared to controls. Furthermore, significantly
lower levels of TLR7 and TLR9 were observed in HPV-
infected SLE than HPV-negative patients. A previous
study reported that infection of human primary kerati-
nocytes with HPV16 E6 and E7 recombinant retro-
viruses can inhibit TLR9 transcription and, hence, result
in functional loss of TLR9-regulated pathways,
Table 4 Effects of clinical variables on the TLR levels in lupus patients (categorical variable)
TLR3 TLR7 TLR8 TLR9
Yes No Yes No Yes No Yes No
n n n n n n n n
Clinical manifestation






18 3.9 ± 2.7 13 12 ± 7 33 12 ± 9 13 12 ± 7 33 12 ± 9






9 4.5 ± 3.0 29 12 ± 9 17 12 ± 9 29 11 ± 8 17 13 ± 9






16 3.9 ± 2.9 13 11 ± 7 33 12 ±
10
13 11 ± 9 33 12 ± 9






4 5.1 ± 1.7 39 13 ± 9 7 8 ± 4 39 11 ± 8 7 18 ±
10






18 4.7 ± 2.7
†










4 5.6 ± 3.0 38 12 ± 8 8 13 ±
10
38 11 ± 9 8 16 ± 9






4 4.1 ± 3.2 36 12 ± 8 10 12 ±
10
36 12 ± 9 10 11 ± 6
Hydroxychloroquine






11 5.2 ± 2.5
†
27 11 ± 7 19 13 ±
11
27 9 ± 7 19 15 ±
10






16 4.0 ± 2.4 16 13 ± 8 30 11 ± 9 16 12 ± 9 30 12 ± 9
Azathioprine






10 4.1 ± 2.8 25 12 ± 9 21 11 ± 8 25 12 ±
10
21 12 ± 7






21 4.0 ± 2.7 8 9.9 ±
5.6
38 12 ± 9 8 13 ±
12
38 11 ± 8
Cyclophosphamide
(oral or IV)






23 3.8 ± 2.5 6 7 ± 5 40 13 ± 9 6 8 ± 10 40 12 ± 9




2 N.A. 24 N.A. 4 13 ± 16 42 11 ± 8 4 13 ± 9 42 12 ± 9
Cyclosporin A






21 3.8 ± 2.5 9 11 ± 7 37 12 ± 9 9 11 ±
12
37 12 ± 8
Current - - - - - - - - - - - - - - - -
Mycophenolate mofetil






21 4.1 ± 2.6 8 15 ± 14 38 11 ± 7 8 11 ± 9 38 12 ± 9






23 4.0 ± 2.6 5 14 ± 10 41 12 ± 8 5 11 ± 9 41 12 ± 9
HPV, human papillomavirus; SLE, systemic lupus erythematosus; TLR, toll-like receptor; † P <0.05
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Table 5 Multiple linear regression with TLR7 and TLR9 expressions as independent variables in lupus patients
Risk factors Adjusted coefficient (95%) P-value Adjusted R2
TLR7 level 0.592
HPV infection -0.815 (-6.827 to -1.751) 0.002
Cumulative dose of prednisolone in the past 15 years, gm -0.356 (-0.014 to -0.001) 0.026
High-risk HPV infection 0.217 (-1.487 to 3.926) 0.359
Hydroxychloroquine therapy ever 0.012 (-1.919 to 2.046) 0.067
TLR9 level 0.391
HPV infection -0.313 (-10.395 to -1.170) 0.015
SLEDAI 0.474 (0.841 to 2.576) < 0.001
Cumulative dose of hydroxychloroquine in the past 15 years, gm -0.268 (-0.012 to 0.000) 0.041
Duration receiving treatment of Azathioprine, month -0.047 (-0.059 to 0.040) 0.706
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Figure 2 Intracellular TLR-regulated pathways and ISGs are inhibited in oncogenic HPV cell lines. (a) Flow cytometry of TLRs. Protein
levels of TLRs 3, 7, 8, and 9 in Caski, HeLa or C33A cells were shown in bar charts as mean fluorescence intensity (MFI). (b) qRT-PCR of ISGs.
Total RNA was extracted from Caski, HeLa or C33A cells. After reverse transcription, qRT-PCR was performed using ISG15 or Mx-1 primers. As
positive control, GAPDH was amplified at exponential phase of 20 cycles. (c) Functionality of TLR-regulated pathways. CaSki, HeLa and C33A cells
were stimulated for 24 h with ligands of TLRs 3, 7, 8, and 9 as indicated in the Figure. Ex vivo production of cytokines including interleukin (IL-6),
IL-8, IL-10 and IL-12p70, tumor necrosis (TNF)-a and IL-1b in culture supernatant was measured by Cytometric Bead Array. Experiments were
repeated three times in triplicate.
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suggesting that the modulation of TLR may be part of a
mechanism by which HPV16 evades innate immunity
[23]. In addition to down-regulating TLR9, we also
reported a notable decrease in TLRs 7 and 8 in CaSki
and HeLa compared to C33A cells. Our findings in cer-
vical samples together with previous evidence [23],
therefore, suggest that abolishing innate responses may
be involved in viral persistence which may ultimately
lead to carcinogenesis mediated by HPVs. Nonetheless,
details of the pathogenic effect of oncogenic HPV on
the host innate immune response remained to be
elucidated.
The type I IFNs response is a strong and crucial mod-
erator for the control of viral infections, in which the
type I IFNs family members engage the ubiquitously
expressed interferon-a/b receptor (IFNAR). Binding to
IFNAR then stimulate more than 300 ISGs, which sub-
sequently induce an antiviral state. The antiviral state is
a collective term for limitation of viral replication, viral
resistance of neighboring cells, and apoptosis of virally
infected cells [16]. In this study, our data revealed that
the antiviral ISG15 and Mx-1 gene expressions were
inhibited by the two oncogenic HPV types, which is
consistent with recent genomewide transcriptome stu-
dies of reduced ISGs expressions in high-risk HPV types
[17-20], subsequently resulting in reduced levels of IFN
and HPV DNA replication [17,20]. Functional data
exploring whether the repression of theses intracellular
TLRs and ISGs have functional consequences for
inflammatory cytokines expression indicated that the
induction of pro-inflammatory cytokines (IL-6, IL-8, IL-
12p70, TNF-a and IL-1b) by TLR ligands (R837, ssRNA
and ODN2395) were greatly impaired in two carcino-
genic HPV cell types than HPV-negative cells. The
down-regulation of the nucleic acid-sensing TLRs (TLRs
7, 8 and 9) ensures that the expression of inducible pro-
inflammatory cytokines is minimized in order to prevent
the expression of antiviral ISGs (ISG15 and Mx-1) of a
biologically relevant antiviral response. Strikingly, no IL-
6 and IL-8 inductions were observed in CaSki cells
when stimulated with the ligand for TLR9, indicating
that the oncogenic viral proteins are able to strongly
inhibit the TLR9 pathway. Further studies are required
to look into the details of the effect of oncogenic HPV
on the avoidance of stimulation and down-regulation of
the immune system, which permits persistence in the
cervical epithelium and oncogenesis, is potential evi-
dently part of an immune evasion strategy used by
oncogenic HPV.
Conclusion
In conclusion, prednisolone and TLR antagonist (hydro-
xychloroquine) may down-regulate expression levels of
TLR7 and TLR9 in lupus patients, thereby decreasing
the innate immune response to HPV infection. Further-
more, upon infection, HPV further down-regulate TLR7
and 9 levels which may favor viral persistence. Reduc-
tion of nucleic acid-sensing TLRs 7, 8 and 9 in carcino-
genic HPVs ensures that the expression of inducible
pro-inflammatory cytokines is minimized in order to
suppress the expression of antiviral ISGs (ISG15 and
Mx-1) of a biologically relevant antiviral response.
Further studies to elucidate the role of immunosuppres-
sants and HPV infectious on TLR expression in SLE,
and whether topical TLR agonists may be useful as ther-
apeutic tools for clearing oncogenic HPV infection in
the cervical epithelial cells are warranted.
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